SOURCE: Easton Pharmaceuticals, Inc.

February 03, 2014 09:31 ET

Easton Pharmaceuticals Announces Update to VIORRA Initiative: Manufacturing Set to Begin

Company Moving Towards Meeting Its Goal of Initial Sales by the End of First Half or Earlier, Calendar Year 2014

TORONTO, ON--(Marketwired - Feb 3, 2014) - Easton Pharmaceuticals (OTC: EAPH) and its Consultants in Mexico, BMV Medica S.A., announce they have advanced a timetable towards a VIORRA product launch in Mexico, Latin America and potentially the US, Canada and other international markets.

Easton Pharmaceuticals on account of BMV Medica and their efforts, has an agreement in principle with a manufacturer in Mexico, audited by the United States FDA (Food and Drug Administration), and currently exporting a product to the United States. This is an important material event for the company, with VIORRA containing all GRAS ingredients (Generally Regarded As Safe), one FDA approved manufacturer could easily supply all North American needs, with considerably less onerous regulatory hurdles internationally resulting in faster access to all markets. Concurrent with the proposed manufacturing agreement, Easton is advancing an additional tranche of funds to BMV Medica as per a prior signed agreement between Easton and BMV.

Once final pricing and other issues have been agreed upon, a definitive agreement will be signed and manufacturing could begin as early as the end of February or soon afterwards, with a sales and marketing launch in Mexico and other markets possible by May of 2014.

Ms. Mendoza Vazquez of BMV Medica stated: "We have been working closely with Easton and the manufacturer, and have only a few details left before signing the final agreement. This is a premium manufacturer, with a successful audit already having been performed by the United States FDA, ensuring a high-quality product will be available all over North America and other parts of the world. We expect and should have a final contract signed very soon."

Carla Pepe, current marketing director of Easton Pharmaceuticals and lead project manager working closely with BMV, commented "We believe the high-quality manufacturing component is an important step in the perception of VIORRA as the intimate use by women necessitates this level of quality. The Company is attempting to take the proper steps to not only get to market with VIORRA as quickly as possible but to do so in a manner that will demonstrate the company has a high quality, safe product thanks to the diligent work of BMV and Dr. Bagi."

As previously stated, BMV is attempting to assure Easton Pharmaceuticals that the company shall receive not only regulatory approval in Mexico, but also a distribution partner to coincide with the regulatory approval. "Viorra" is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal FSAD (Female Sexual Arousal Disorder), VIORRA is a topical, daily-use product formulated with ingredients classified by the FDA as Generally Recognized as Safe.

In other developments, Easton Pharmaceuticals has executed and closed on an agreement regarding its Medical Marijuana Initiatives. A formal announcement is expected within a few days as well as possible other HEMP related OTC products Easton has been formulating.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company that owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals product "VIORRA", is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are conservatively estimated to be in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.

For More Information Visit &

Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "could", "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings which all investors are advised to view.